Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state.
Gandjbakhch F, Conaghan PG, Ejbjerg B, Haavardsholm EA, Foltz V, Brown AK, Møller Døhn U, Lassere M, Freeston J, Bøyesen P, Bird P, Fautrel B, Hetland ML, Emery P, Bourgeois P, Hørslev-Petersen K, Kvien TK, McQueen F, Ostergaard M. Gandjbakhch F, et al. Among authors: fautrel b. J Rheumatol. 2011 Sep;38(9):2039-44. doi: 10.3899/jrheum.110421. J Rheumatol. 2011. PMID: 21885514
Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity.
Gandjbakhch F, Haavardsholm EA, Conaghan PG, Ejbjerg B, Foltz V, Brown AK, Døhn UM, Lassere M, Freeston JE, Olsen IC, Bøyesen P, Bird P, Fautrel B, Hetland ML, Emery P, Bourgeois P, Hørslev-Petersen K, Kvien TK, McQueen FM, Østergaard M. Gandjbakhch F, et al. Among authors: fautrel b. J Rheumatol. 2014 Feb;41(2):398-406. doi: 10.3899/jrheum.131088. Epub 2013 Dec 15. J Rheumatol. 2014. PMID: 24334647
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC. Tanaka Y, et al. Among authors: fautrel b. Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30. Ann Rheum Dis. 2019. PMID: 31040122 Free PMC article. Clinical Trial.
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F, Kannowski CL, Nicolay C, Kadziola Z, De La Torre I, Fleischmann R. Fautrel B, et al. RMD Open. 2020 Apr;6(1):e001131. doi: 10.1136/rmdopen-2019-001131. RMD Open. 2020. PMID: 32371431 Free PMC article.
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools.
Burmester GR, Álvaro-Gracia JM, Betteridge N, Calvo Alén J, Combe B, Durez P, Fautrel B, Ferreira RJO, Gabay C, Iagnocco A, Montecucco C, Østergaard M, Ramiro S, Rubbert-Roth A, Stamm T, Szekanecz Z, Taylor PC, van de Laar M. Burmester GR, et al. Among authors: fautrel b. Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1056-1067. Epub 2020 Nov 17. Clin Exp Rheumatol. 2020. PMID: 33253107 Free article.
388 results